Sep 14, 2017 1 min read

CANONSBURG — Mylan N.V. said Thursday it launched norethindrone acetate and ethinyl estradiol tablets USP, and ferrous fumarate tablets, 1 mg/20 mcg, which is indicated for use by women to prevent pregnancy. Mylan subsidiary, Mylan Laboratories Limited, received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is a generic version of Allergan’s Minastrin 24 FE Tablets.

The company said in a press release the launch of the tablets further strengthens its women’s healthcare portfolio, one of 10 therapeutic franchise priority areas for the company — from cancer and hypothyroidism, to cardiovascular disease and diabetes — to help women manage a multitude of health conditions through a suite of medicines.

Minastrin tablets had U.S. sales of approximately $346.9 million for the 12 months ending July 31, according to QuintilesIMS Health.

Mylan is a global pharmaceutical company incorporated in the Netherlands with its administrative headquarters in Southpointe.